Skip to content
Insider tapeFilings through Fri, Oct 2
Watchlist

Duncan Mckechnie

Evp, Chief Commercial Officer at Vertex Pharmaceuticals Inc / Ma (VRTX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $5.7M

Reported trades

Filed Stock Type Shares Price Value Since
Jul 7SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 1,541 $519.00 $800K -3.0%
Mar 13SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,633 $498.42 $1.3M +1.0%
Mar 6SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,437 $475.30 $1.2M +5.9%
Feb 26SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,500 $486.35 $1.2M +3.5%
Feb 26SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,410 $489.00 $1.2M +3.0%
  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $800K of VRTX at $519.00 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.3M of VRTX at $498.42 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.2M of VRTX at $475.30 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.2M of VRTX at $486.35 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.2M of VRTX at $489.00 — pre-scheduled 10b5-1 plan sale.